Zura Bio (ZURA) announced the launch of TibuSURE, a Phase 2 global study evaluating tibulizumab for the treatment of systemic sclerosis in adults. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on ZURA: Zura Bio to Present at Healthcare Conference Zura Bio Announces Phase 2 Tibulizumab Study Zura Bio submits protocol to FDA for Phase 2 study of Tibulizumab Zura Bio price target raised to $12 from $11 at Chardan Zura Bio Limited: Q3 2024 Financial Insights and Strategic Progress
